Search Results

Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on Wave’s WVE-003 clinical-stage Huntington’s disease program—a potential $5 billion commercial opportunity, according to the biotech.

Wave Life Sciences Ltd., a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer.

Wave Life Sciences Ltd. provided an update on its best-in-class small interfering RNA and RNA editing platform capabilities.

Wave Life Sciences Ltd. announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in April.

Wave Life Sciences Ltd. will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 9, 2024, to review the company’s first quarter 2024 financial results and provide business updates.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced upcoming presentations at the 2nd Annual Obesity & Weight Loss Drug Development Summit and the 5th Annual RNA Editing Summit, both taking place in Boston on June 11-13 and June 18-20, respectively.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.